Skip to main content

A Cost-Effective Antibody Cocktail For Broad Neutralization Of Human Type I IFN Activity

Hero Region
An anti-IFN-Alpha, anti-IFN-Beta, and anti-IFNAR2 antibody mixture substantially improved neutralization of Human Type I IFN activity


A single anti-human IFN receptor 2 (IFNAR2) monoclonal antibody (cat. # 21385-1) has proven to be useful in neutralizing the activities of human Type I IFNs by blocking the Type I IFN receptor complex.1-3  However, a high amount of this antibody is sometimes required to effectively compete for the receptor complex in the presence of multiple Type I IFNs (e.g. IFN alpha, beta, and omega) that are present in certain samples.

A cost-effective and performance-enhancing alternative is to employ an antibody mixture consisting of anti-human IFNAR2 monoclonal antibody, anti-human IFN alpha polyclonal antibody, and anti-human IFN beta polyclonal antibody (39000-1). The inclusion of the two polyclonals reduces the amount of anti-human IFNAR2 monoclonal antibody required and improves neutralization of multiple Type I IFNs often found in complex samples.

A human cell line responsding to all Type I IFNs was used to measured IFN activity.

The anti-IFN-alpha antibody also exhibits cross-reactivity with IFN-omega.

The anti-IFN-beta exhibited no cross-reactivity with IFN-alpha. IFN pool included IFN alpha, beta, and omega.

The anti-IFNAR2 binds to the receptor, effectively neutralizing all Type I IFNs.



1.  Schijf et al., PLOS ONE, 2013, 8(11):e81695 

2.  Davis et al., J. Immunol., 2008, 181:8204

3.  Nestle et al., JEM, 2005, 202(1):135



Human Type I IFNs neutralization

Type 1 IFN neutralizing antibodies


Multiple Type interferons



Gerenal ELISA plate

Related Article

Introduction to Antibodies

Read Article